For patients with metastatic colorectal cancer(mCRC)who achieve disease control during first-line standard therapy,post-induction strategies should emphasize on quality of life improvement while maintaining disease control.Chemotherapy combined with anti-epidermal growth factor receptor(EGFR)monoclonal antibody is the standard first-line treatment for RAS wild-type mCRC patients.After anti-EGFR-based first-line induction therapy achieves at least stable disease,anti-EGFR-based maintenance treatment could maintain disease control while keeping a good safety profile.Based on research evidence and clinical practice,the Chinese expert consensus on anti-EGFR-based maintenance strategy for RAS wild-type mCRC aims to further clarify the treatment timing,regimen options,adverse reaction management and follow-up strategy,providing standardized guidance to maximize the clinical benefit in RAS wild-type mCRC.
维普
万方数据